İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2020 · article

A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy

YÖKSİS OpenAlex Açık erişim · diamond
Yıl2020
Atıf5OpenAlex
Atıf4Semantic Scholar · 1 etkili
Yüzdelik%61,7
FWCI0,31,00 = dünya ortalaması
Scopus (SJR)Q3
WoS (JCR)Q4

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıJournal of cancer research and therapeutics
  • Katalog eşleşmesi (ISSN)Journal of Cancer Research and Therapeutics
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

BACKGROUND: The most common age at which gastric cancer is diagnosed is 70 years, and the majority of patients diagnosed are at the metastatic stage. However, although gastric cancer is a geriatric disease, there is no suggestion to discriminate treatment for the general geriatric patient population. Here, we evaluated patients receiving palliative chemotherapy for gastric cancer owing to advanced age. PATIENTS AND METHODS: Multicenter data of geriatric patients receiving palliative chemotherapy because of metastatic gastric cancer were retrospectively reviewed. RESULTS: In total, 262 geriatric patients with gastric cancer were included in the study. Of these, 167 patients, including 134 (51.8%) patients with metastasis at diagnosis and 33 patients with relapse after surgery, were evaluated for palliative therapy. Chemotherapy was started in 87 (52.1%) of 167 patients. The overall median survival of the patients receiving chemotherapy was 9.3 months. There was no difference in overall survival (OS) between patients aged >70 and <70 years. However, a significant difference was detected in OS of patients depending on their Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment; survival was 15 months in the group with PS 0-1 and 7 months in the group with PS ≥2. CONCLUSION: Advanced age chemotherapy receiving rates in patients with metastatic gastric cancer is decreasing. Survival is not associated with age, but pretreatment ECOG PS is important. Therefore, ECOG PS and comorbidities should be evaluated in detail, and combination therapies could contribute to patient survival.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

5atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

8
  1. ALİ MURAT TATLI 1
  2. ZUHAT URAKÇI DİCLE ÜNİVERSİTESİ 2
  3. DİDEM TAŞTEKİN İSTANBUL ÜNİVERSİTESİ 3
  4. DOĞAN KOCA 4
  5. SEMA SEZGİN GÖKSU 5
  6. ÜMMÜGÜL ÜYETÜRK 6
  7. MUHAMMET ALİ KAPLAN DİCLE ÜNİVERSİTESİ 7
  8. HASAN ŞENOL COŞKUN 8